{"DataElement":{"publicId":"5026631","version":"1","preferredName":"Prior Agent Intervention And Therapy-Related Toxicity Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded response as to whether a patient meets the eligibility criteria addressing prior agents that produce an effect, or alter the course of a disease in a patient and their associated  toxicities.","longName":"AGNT_TOX_ELIG_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5026613","version":"1","preferredName":"Prior Agent Intervention And Therapy-Related Toxicity Clinical Trial Eligibility Criteria","preferredDefinition":"Earlier in time or order._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._The finding of bodily harm due to the poisonous effects associated with the action or administration of therapeutic agents.               _Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"3419199v1.0:5026651v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"3419199","version":"1","preferredName":"Prior Agent","preferredDefinition":"Earlier in time or order.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C25629:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB9DDEC4-8766-24B8-E040-BB89AD437E22","latestVersionIndicator":"Yes","beginDate":"2012-03-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2012-03-19","modifiedBy":"ONEDATA","dateModified":"2012-03-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5026651","version":"1","preferredName":"Intervention or Procedure And Therapy-Related Toxicity Clinical Trial Eligibility Criteria","preferredDefinition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.:An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.:The finding of bodily harm due to the poisonous effects associated with the action or administration of therapeutic agents.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C25218:C37912:C42607:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intervention or Procedure","conceptCode":"C25218","definition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapy-Related Toxicity","conceptCode":"C42607","definition":"The finding of bodily harm due to the poisonous effects associated with the action or administration of therapeutic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E4F3C3-40B9-B758-E050-BB89AD43375A","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"ONEDATA","dateModified":"2015-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E452F8-86D4-7E82-E050-BB89AD4304BA","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9/30/15 approved & released/tt_9/29/15 tt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000494","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Theradex - 1","type":"Alternate Question Text","description":"Have a minimum of 7 days elapsed from the last dose of prior EGFR inhibitor and resolution of any drug-related toxicity to less than or equal to grade 2 except for alopecia?","url":null,"context":"Theradex"},{"name":"Have a minimum of 7 days elap","type":"Preferred Question Text","description":"Have a minimum of 7 days elapsed from the last dose of any agent and the resolution of associated drug-related toxicities?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has patient been off prior therapy with any investigational agent administered as part of a Phase 0 study (also referred to as an \"early Phase I study\" or \"pre-Phase I study\" where a sub-therapeutic dose of drug is administered) at the Coordinating Center PI's discretion less than 2 weeks and failed to recover to eligibility levels from any toxicities?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient has received prior anti-CTLA-4, have a minimum of 12 weeks elapsed from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose, and there is no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE version 4.0)?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has received prior anti-CTLA-4 have a minimum of 12 weeks elapsed from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose, and there is no history of severe immune-related adverse effects from anti-CTLA-4?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient has had prior treatment with anti-CTLA-4 are the following requirements met: minimum of 12 weeks from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE 4.0)?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Does patient have toxicity greater than grade 1 from prior therapy (except alopecia or anorexia)?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient has had prior treatment with anti-CTLA-4 are the following requirements met: minimum of 12 weeks from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE 5.0)?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient has received prior experimental (non-FDA approved therapy or immunotherapies, this therapy was last administered more than 30 days or five half-lives of the drug (whichever is less) prior to the initiation of study treatment and patient must have fully recovered from any acute effects of these therapies?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Does patient have unresolved grade 2 toxicity from prior therapy (except alopecia or anorexia)?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Have a minimum of 7 days elapsed from the last dose of prior EGFR inhibitor and resolution of any drug-related toxicity to less than or equal to grade 1 except for alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient has received prior anti-CTLA-4, have a minimum of 12 weeks elapsed from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose, and there is no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE version 5.0)?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If patient has had prior treatment with anti-CTLA-4 are the following requirements met: minimum of 12 weeks from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient has received prior bevacizumab or other experimental therapies, was therapy discontinued at least 4 weeks prior to treatment start or randomization and patient has recovered from toxicities to less than Grade 2?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient has received prior anti-CTLA-4, has a minimum of 12 weeks elapsed from the first dose of anti-CTLA-4 and more than 6 weeks from the last dose, and there is no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E49FDE-086C-DE2F-E050-BB89AD434A31","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-09-29","modifiedBy":"TYRRELLM","dateModified":"2023-07-21","changeDescription":"9/30/15 approved&release/tt_9/29/15 - 9910/tt.","administrativeNotes":"7/21/23 removed special characters from AQT_mmt","unresolvedIssues":null,"deletedIndicator":"No"}}